Honokiol ameliorates angiotensin II ‐induced cardiac hypertrophy by promoting dissociation of the Nur77–LKB1 complex and activating the AMPK pathway
Journal of Cellular and Molecular Medicine · 2024-01 · 28 (1)
DOI: 10.1111/jcmm.18028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 20.11.2023. Verfasst von Xiaoyan Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Echocardiological Department, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Angiotensin II, AMP-Activated Protein Kinases, Allyl Compounds, Biphenyl Compounds. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Medical University, Fujian Provincial Department of Science and Technology, Fujian Provincial Health Technology Project.
Abstract (Originalsprache)
Pathological cardiac hypertrophy is a key contributor to heart failure, and the molecular mechanisms underlying honokiol (HNK)‐mediated cardioprotection against this condition remain worth further exploring. This study aims to investigate the effect of HNK on angiotensin II (Ang II)‐induced myocardial hypertrophy and elucidate the underlying mechanisms. Sprague–Dawley rats were exposed to Ang II infusion, followed by HNK or vehicle treatment for 4 weeks. Our results showed that HNK treatment protected against Ang II‐induced myocardial hypertrophy, fibrosis and dysfunction in vivo and inhibited Ang II‐induced hypertrophy in neonatal rat ventricular myocytes in vitro . Mechanistically, HNK suppressed the Ang II‐induced Nur77 expression at the transcriptional level and promoted ubiquitination‐mediated degradation of Nur77, leading to dissociation of the Nur77–LKB1 complex. This facilitated the translocation of LKB1 into the cytoplasm and activated the LKB1‐AMPK pathway. Our findings suggest that HNK attenuates pathological remodelling and cardiac dysfunction induced by Ang II by promoting dissociation of the Nur77–LKB1 complex and subsequent activation of AMPK signalling. This study uncovers a novel role of HNK on the LKB1‐AMPK pathway to protect against cardiac hypertrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Echocardiological Department, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Cardiovascular Department, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Cardiovascular Department, National Regional Medical Center, Binhai Branch of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Dajun Chai
Förderung
- Fujian Medical University
- Fujian Provincial Department of Science and Technology
- Fujian Provincial Health Technology Project
- Natural Science Foundation of Fujian Province
Zitieren
APA
Lin, X., Zhang, H., Chu, Y., Zhang, Y., Xu, C., Xie, H., Ruan, Q., Lin, J., Huang, C. K., & Chai, D. (2024). Honokiol ameliorates angiotensin II ‐induced cardiac hypertrophy by promoting dissociation of the Nur77–LKB1 complex and activating the AMPK pathway. Journal of Cellular and Molecular Medicine, 28(1). https://doi.org/10.1111/jcmm.18028
Vancouver
Lin X, Zhang H, Chu Y, Zhang Y, Xu C, Xie H, et al. Honokiol ameliorates angiotensin II ‐induced cardiac hypertrophy by promoting dissociation of the Nur77–LKB1 complex and activating the AMPK pathway. Journal of Cellular and Molecular Medicine. 2024;28(1). doi:10.1111/jcmm.18028
BibTeX
@article{Lin2024,
author = {Lin, Xiaoyan and Zhang, Hailin and Chu, Yong and Zhang, Yuze and Xu, Changsheng and Xie, Hong and Ruan, Qinyun and Lin, Jinxiu and Huang, Chun-Kai and Chai, Dajun},
title = {Honokiol ameliorates angiotensin II ‐induced cardiac hypertrophy by promoting dissociation of the Nur77–LKB1 complex and activating the AMPK pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {1},
doi = {10.1111/jcmm.18028}
}
EUVIMED